22 results
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
14 Oct 22
Regulation FD Disclosure
11:32am
(years): mean (range) 56 (24-81) Sex: n (%) Male 50 (49%) Female 53 (51%) Race: n (%) American Indian or Alaskan Native 4 (4%) Asian 4 (4%) Black
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
19 May 22
Regulation FD Disclosure
7:43am
Milestones Exciting 2022 News Cadence Ongoing Partnering Discussions with Leading Ophthalmic Companies (including European and Asian Players) 2021 2022
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
29 Mar 22
Regulation FD Disclosure
8:25am
(%) African American n (%) Asian n (%) Other^ n (%) ^includes American Indian or Alaska Native; Native Hawaiian or Other Pacific Islander 182 (74.6 … 2022 News Cadence Ongoing Partnering Discussions with Leading Ophthalmic Companies (including European and Asian Players) 2021 2022 Report Positive
8-K
EX-99.2
0m3x8rhj
5 Jan 22
Completed Enrollment of Nyxol® LYNX-1 Phase 3 NVD Trial
7:05am
8-K
EX-99.2
iv31rdv8y1p45naqpm
15 Nov 21
Ocuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update
12:00am
8-K
EX-99.2
z8vj7xz8b j4
12 Aug 21
Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update
7:31am
8-K
EX-99.1
qdepo5fatsply9
30 Jun 21
Regulation FD Disclosure
9:17am
8-K
EX-99.1
nmhsg4e7hy
6 Jan 21
Ocuphire Corporate Presentation January 2021
7:37am
8-K
EX-99.2
qcnhz
6 Nov 20
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
9:18am
DEFM14A
e86qj5d9y3pme 647
29 Apr 05
Proxy related to merger
12:00am